Diamond Hill Capital Management LLC Investment Advisor Makes New Investment in Illumina, Inc. $ILMN

Diamond Hill Capital Management LLC Investment Advisor acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 301,642 shares of the life sciences company’s stock, valued at approximately $53,038,000. Diamond Hill Capital Management LLC Investment Advisor owned approximately 0.20% of Illumina as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Elyxium Wealth LLC purchased a new position in shares of Illumina in the 4th quarter valued at approximately $25,000. TD Waterhouse Canada Inc. purchased a new stake in shares of Illumina in the fourth quarter worth $26,000. Laurel Wealth Advisors LLC bought a new stake in Illumina during the 4th quarter valued at about $26,000. Activest Wealth Management increased its position in shares of Illumina by 671.9% during the fourth quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 215 shares in the last quarter. Finally, Quarry LP purchased a new position in shares of Illumina in the third quarter worth $32,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on ILMN shares. Stifel Nicolaus raised their target price on shares of Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Zacks Research raised Illumina from a “hold” rating to a “strong-buy” rating in a report on Monday, August 3rd. Sanford C. Bernstein restated a “market perform” rating and issued a $215.00 price target on shares of Illumina in a research note on Friday, July 31st. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Finally, Royal Bank Of Canada upped their price objective on Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Illumina currently has an average rating of “Hold” and a consensus target price of $188.40.

Illumina Price Performance

NASDAQ ILMN opened at $190.89 on Monday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The business’s fifty day moving average is $183.78 and its 200 day moving average is $150.54. The company has a market capitalization of $28.82 billion, a PE ratio of 35.61, a price-to-earnings-growth ratio of 2.69 and a beta of 1.44. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $207.00.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter last year, the company earned $1.19 earnings per share. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Sell-side analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current year.

Insider Activity

In other Illumina news, Director Keith A. Meister sold 283,269 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $199.61, for a total transaction of $56,543,325.09. Following the sale, the director owned 2,089,425 shares in the company, valued at approximately $417,070,124.25. This trade represents a 11.94% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Scott D. Ericksen sold 500 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $160.00, for a total transaction of $80,000.00. Following the completion of the transaction, the chief accounting officer owned 14,446 shares of the company’s stock, valued at approximately $2,311,360. The trade was a 3.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,415,351 shares of company stock worth $255,966,311 in the last quarter. 2.90% of the stock is currently owned by insiders.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.